MGMT and cancer: The recently developed FM-HCR assays and fluorescent NR-1 probe both overcome the problems associated with currently used indirect methods of measuring MGMT activity, and merit consideration as alternatives for use in pre-clinical studies and in clinical trials involving cancers where MGMT status may be associated with therapeutic outcomes.